AKBA Stock Analysis: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$1.03
-0.04 (-3.30%)
▼
5d:
-10.87%
30d:
-27.05%
90d:
-14.58%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
AKBA is down 8.6% this week, but smart money is accumulating calls. Top strike: $1.5 2026-07-17 with 1,348 OI. Call ratio: 94% View Scanner →
Strength: 8.7/10
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
15 traders called AKBA this week
67% bullish • 8 bearish
67% bullish • 8 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AKBA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AKBA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $1.02, which is considered oversold relative to its 30-day fair value range of $1.20 to $1.49. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.6) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: AKBA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.20 (+296.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AKBA is in a downtrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: AKBA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.20 (+296.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.20 -
$1.49
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 296.2% below Wall St target ($4.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: 5-day price weakness (-10.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.20 -
$1.49
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.04
Resistance Level
$1.54
Current Trend
Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.58
Wall Street Target
$4.20
(+296.2%)
Revenue Growth (YoY)
-6.6%
Profit Margin
-8.8%
PE vs Historical
-5.6 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: May 18, 2026 1:01 PM ET
Data refreshes hourly during market hours. Next update: 2:01 PM
Data refreshes hourly during market hours. Next update: 2:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
John P Butler
BUY
69270 shares
2026-03-04
Richard C Malabre
SELL
49524 shares
2026-02-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
